Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2017-10-02 Transaction in Own Shar…
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement of transactions under Novozymes' stock buyback program, including number of shares purchased, transaction values, and trading data. It references the stock buyback program initiated in 2017 and provides detailed trading data for specific dates. There is no indication of financial statements, earnings, management discussion, or other report types. The content is focused on the company's repurchase of its own shares, which fits the category of Transaction in Own Shares (POS). The document length is substantial and contains detailed transaction data, not just a brief announcement or reference to a report. Therefore, the correct classification is POS with high confidence.
2017-10-02 English
Transaction in Own Shares 2017
Transaction in Own Shares Classification · 100% confidence The document text is very short (269 characters) and explicitly states that Novozymes bought back a specific number of shares under a previously announced share repurchase program ('aktietilbagekøbsprogram'). It concludes with 'Læs hele meddelelsen i PDF format' (Read the full announcement in PDF format). This structure—a brief update on share transactions followed by a prompt to read the full document—strongly suggests this is an announcement about the transaction rather than the detailed regulatory filing itself. The content directly relates to the company buying back its own shares. Therefore, the most appropriate classification is Transaction in Own Shares (POS).
2017-09-25 Danish
Transaction in Own Shares 2017
Transaction in Own Shares Classification · 99% confidence The document explicitly details transactions made under a 'stock buyback program' by Novozymes, providing accumulated figures, daily transaction volumes, average purchase prices, and detailed trade logs (Venue, Volume, Price, Time). This content directly relates to the company purchasing its own shares. According to the definitions, 'Transaction in Own Shares (Code: POS)' is the category for 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. The document is a detailed report, not just an announcement of a report, and its length (over 100k characters) confirms it is the primary data, not an RPA or RNS.
2017-09-25 English
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 85% confidence The document is a brief announcement detailing the number of shares the company has repurchased under its existing stock buyback program, including transaction value and reference to the original program announcement. This is a classic report of a transaction in the company’s own shares.
2017-09-25 English
Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement of Novozymes' share buy-back transactions under a repurchase program, including transaction dates, number of shares, prices, and total values. It references compliance with EU Market Abuse Regulation and provides extensive trading data. The content focuses on the company's repurchase of its own shares, the total shares held, and the program's progress. There is no indication of financial statements, earnings data, management discussion, or other report types. The document is not a report itself but an announcement of share repurchase activity. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is substantial and contains detailed transactional data, supporting a high confidence in classification.
2017-09-25 English
Transaction in Own Shares 2017
Transaction in Own Shares Classification · 100% confidence The document text explicitly states that Novozymes has purchased an accumulated number of shares under a stock buyback program. This action, the repurchase of own shares, directly corresponds to the definition of 'Transaction in Own Shares'. The document is very short (284 chars) and mentions reading the full announcement in PDF, which might suggest RPA, but the core content is a specific transaction report, making POS the most accurate classification for the *subject matter* being reported, even if it's a brief summary announcement.
2017-09-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.